Download presentation
Presentation is loading. Please wait.
Published byTuomo Kouki Modified over 5 years ago
1
Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1) or placebo in patients with idiopathic pulmonary fibrosis (IPF). Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1) or placebo in patients with idiopathic pulmonary fibrosis (IPF). CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. Reproduced from [23]. Jürgen Behr Eur Respir Rev 2013;22: ©2013 by European Respiratory Society
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.